keyword
MENU ▼
Read by QxMD icon Read
search

muscle invasive urothelial bladder cancer

keyword
https://www.readbyqxmd.com/read/28802887/clinical-outcomes-of-patients-with-t1-nested-variant-of-urothelial-carcinoma-compared-to-pure-urothelial-carcinoma-of-the-bladder
#1
Abhijith D Mally, Amy L Tin, Justin K Lee, Prassannah Satasivam, Eugene K Cha, S Michele Donat, Harry W Herr, Bernard H Bochner, Daniel D Sjoberg, Guido Dalbagni
PURPOSE: Evaluate oncologic outcomes of patients with cT1 nested variant (NV) of urothelial carcinoma (UC) and compare with cases of pure UC of the bladder. MATERIALS AND METHODS: We retrospectively identified 30 patients with NV who, between 1997 and 2012, underwent transurethral resection with T1 tumor stage, followed by restaging transurethral resection within 3 months confirming non-muscle-invasive disease. Radical cystectomy within 3 months of restaging transurethral resection was considered "early" treatment...
July 14, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28789929/commentary-on-comprehensive-transcriptional-analysis-of-early-stage-urothelial-carcinoma-hedegaard-j-lamy-p-nordentoft-i-algaba-f-h%C3%A3-yer-s-ulh%C3%A3-i-bp-vang-s-reinert-t-hermann-gg-mogensen-k-thomsen-mb-nielsen-mm-marquez-m-segersten-u-aine-m-h%C3%A3-glund-m-birkenkamp
#2
Byron H Lee
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into 3 major classes with basal- and luminal-like characteristics and different clinical outcomes. Large differences in biological processes such as the cell cycle, epithelial-mesenchymal transition, and differentiation were observed. Analysis of transcript variants revealed frequent mutations in genes encoding proteins involved in chromatin organization and cytoskeletal functions...
August 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28766915/metabolomics-analysis-reveals-distinct-profiles-of-nonmuscle-invasive-and-muscle-invasive-bladder-cancer
#3
Divya Sahu, Yair Lotan, Bryan Wittmann, Bruce Neri, Donna E Hansel
Urothelial carcinoma is the most common form of bladder cancer, but pathway changes that occur with stage-wise progression have not been well defined. We used a metabolomics approach to identify potential metabolic pathways uniquely altered in normal urothelium, nonmuscle-invasive bladder cancer (NMIBC), and muscle-invasive bladder cancer (MIBC). We performed global metabolomic profiling using GC-mass spectrometry (MS) and LC-MS platforms to identify metabolite signatures between normal urothelium and high-grade urothelial carcinoma of different stages...
August 1, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28761743/checkpoint-inhibitors-in-the-treatment-of-urological-malignancies
#4
REVIEW
Lazar S Popovic, Gorana Matovina-Brko, Maja Popovic
Checkpoint inhibitors are monoclonal antibodies attach to several different receptors on T-cells or tumour cells expressing receptors for cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1) and their ligand (PD-L1). Since 2010, numerous trials on different tumour types have been conducted, which was resulted in these drugs being approved for the treatment of melanoma, lung cancer, Hodgkin's lymphoma and head and neck cancers. Urological cancers, especially urothelial and renal-cell carcinomas, are immunogenic tumours...
2017: ESMO Open
https://www.readbyqxmd.com/read/28753879/robot-assisted-versus-open-radical-cystectomy-in-patients-receiving-perioperative-chemotherapy-for-muscle-invasive-bladder-cancer-the-oncologist-s-perspective-from-a-multicentre-study
#5
Andrea Necchi, Gregory R Pond, Marc C Smaldone, Sumanta K Pal, Kevin Chan, Yu-Ning Wong, Rosalia Viterbo, Guru Sonpavde, Lauren C Harshman, Simon Crabb, Ajjai Alva, Simon Chowdhury, Ugo De Giorgi, Sandy Srinivas, Neeraj Agarwal, Aristotelis Bamias, Jack Baniel, Ali-Reza Golshayan, Sylvain Ladoire, Cora N Sternberg, Linda Cerbone, Evan Y Yu, Joaquim Bellmunt, Ulka Vaishampayan, Gunter Niegisch, Syed Hussain, Daniel W Bowles, Rafael Morales-Barrera, Matthew I Milowsky, Christine Theodore, Dominik R Berthold, Srikala S Sridhar, Thomas Powles, Jonathan E Rosenberg, Matthew D Galsky
BACKGROUND: Little is known about the outcomes of robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) combined with perioperative chemotherapy for muscle-invasive urothelial bladder cancer (UBC). OBJECTIVE: To evaluate surgical and oncological outcomes for RARC and ORC in multimodal treatment. DESIGN, SETTING, AND PARTICIPANTS: Data from 28 centres were collected for cystectomies performed between January 2000 and July 2013...
March 31, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753816/impact-of-high-risk-features-and-effect-of-neoadjuvant-chemotherapy-in-urothelial-cancer-patients-with-invasion-into-the-lamina-propria-on-transurethral-resection-in-the-absence-of-deep-muscle-invasion
#6
Michael J Metcalfe, James E Ferguson, Roger Li, Lianchun Xiao, Charles C Guo, Bogdan A Czerniak, Arlene Siefker-Radtke, Shanna M Pretzsch, Neema Navai, David J McConkey, Ashish M Kamat, Mathew Campbell, Colin Dinney
BACKGROUND: High-risk non-muscle-invasive bladder cancer (NMIBC) that invades into the lamina propria is frequently understaged and is associated with a risk of lymph node metastasis and death. OBJECTIVE: To identify high-risk features (HRFs) for NMIBC that may identify patients with poorer prognosis who may benefit from neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We performed a single-center retrospective review of patients who underwent RC for NMIBC with invasion into the lamina propria between 1995 and 2013...
July 13, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28749918/immunotherapy-in-urothelial-cancer-part-2-adjuvant-neoadjuvant-and-adjunctive-treatment
#7
Steven S Yu, Leslie K Ballas, Eila C Skinner, Tanya B Dorff, Sarmad Sadeghi, David I Quinn
Urothelial cancer, which is predominantly seen in men, is common throughout the world. Most disease presents as non-muscle invasive bladder cancer (NMIBC), with cancer recurring or progressing to muscle invasive disease in more than 50% of patients after initial therapy. NMIBC is an immune responsive disease, as indicated by the use of intravesical bacillus Calmette-Guérin as treatment for more than 3 decades. The advent of T-cell checkpoint inhibitors, especially those directed at programmed death 1 (PD-1) and its ligand (PD-L1), has had a significant impact on the therapy of advanced urothelial cancer...
July 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28749907/immunotherapy-in-urothelial-cancer-part-1-t-cell-checkpoint-inhibition-in-advanced-or-metastatic-disease
#8
Steven S Yu, Tanya B Dorff, Leslie K Ballas, Sarmad Sadeghi, Eila C Skinner, David I Quinn
Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this disease present as non-muscle-invasive bladder cancer (NMIBC), with cancer recurrence or progression to muscle-invasive cancer in more than 50% of patients after initial therapy. NMIBC is an immune-responsive disease, as indicated by the use of intravesical bacillus Calmette-Guérin as treatment for more than 3 decades. More recently, immunotherapy has seen much progress in a variety of cancers, including advanced and metastatic bladder cancer, in which historical 5-year survival rates are approximately 15%...
June 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28743162/contemporary-use-trends-and-survival-outcomes-in-patients-undergoing-radical-cystectomy-or-bladder-preservation-therapy-for-muscle-invasive-bladder-cancer
#9
David B Cahn, Elizabeth A Handorf, Eric M Ghiraldi, Benjamin T Ristau, Daniel M Geynisman, Thomas M Churilla, Eric M Horwitz, Mark L Sobczak, David Y T Chen, Rosalia Viterbo, Richard E Greenberg, Alexander Kutikov, Robert G Uzzo, Marc C Smaldone
BACKGROUND: The current study was performed to examine temporal trends and compare overall survival (OS) in patients undergoing radical cystectomy (RC) or bladder-preservation therapy (BPT) for muscle-invasive urothelial carcinoma of the bladder. METHODS: The authors reviewed the National Cancer Data Base to identify patients with AJCC stage II to III urothelial carcinoma of the bladder from 2004 through 2013. Patients receiving BPT were stratified as having received any external-beam radiotherapy (any XRT), definitive XRT (50-80 grays), and definitive XRT with chemotherapy (CRT)...
July 25, 2017: Cancer
https://www.readbyqxmd.com/read/28743155/neoadjuvant-chemotherapy-prior-to-radical-cystectomy-for-muscle-invasive-bladder-cancer-with-variant-histology
#10
Malte W Vetterlein, Stephanie A M Wankowicz, Thomas Seisen, Richard Lander, Björn Löppenberg, Felix K-H Chun, Mani Menon, Maxine Sun, Justine A Barletta, Toni K Choueiri, Joaquim Bellmunt, Quoc-Dien Trinh, Mark A Preston
BACKGROUND: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non-organ-confined disease and overall survival after radical cystectomy (RC) in patients with histological variants. METHODS: Querying the National Cancer Data Base, the authors identified 2018 patients with histological variants who were undergoing RC for bladder cancer between 2003 and 2012...
July 25, 2017: Cancer
https://www.readbyqxmd.com/read/28693265/overexpression-of-the-transmembrane-protein-bst-2-induces-akt-and-erk-phosphorylation-in-bladder-cancer
#11
Yoshinori Shigematsu, Naohide Oue, Yuri Nishioka, Naoya Sakamoto, Kazuhiro Sentani, Yohei Sekino, Shoichiro Mukai, Jun Teishima, Akio Matsubara, Wataru Yasui
Bladder cancer, the majority of which is urothelial carcinoma (UC), is a common malignancy worldwide. Genes encoding transmembrane/secretory proteins expressed specifically in certain cancers may be ideal biomarkers for cancer diagnosis and may represent therapeutic targets. In the present study, the expression and function of the bone marrow stromal cell antigen 2 (BST2) gene was analyzed in UC. Reverse transcription-quantitative polymerase chain reaction demonstrated that expression of BST2 in normal tissue samples was the highest in liver tissue...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28688231/exosomes-of-invasive-urothelial-carcinoma-cells-are-characterized-by-a-specific-mirna-expression-signature
#12
Sophie Baumgart, Sebastian Hölters, Carsten-Henning Ohlmann, Rainer Bohle, Michael Stöckle, Marie Stampe Ostenfeld, Lars Dyrskjøt, Kerstin Junker, Joana Heinzelmann
Muscle-invasive bladder cancer (MIBC) represents a highly aggressive tumor type compared to non-muscle-invasive tumors. MIBC is characterized by specific molecular alterations, which may also modulate extracellular tumorigenic effects. Tumor-associated exosomes, especially exosomal miRNAs, are important regulators in the interaction between tumor cells and tumor microenvironment by affecting tumor-promoting processes in target cells. It is important to analyze whether their exosomal patterns also reflect the specific molecular characteristics of MIBC...
May 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28683471/non-invasive-prediction-of-recurrence-in-bladder-cancer-by-detecting-somatic-tert-promoter-mutations-in-urine
#13
Françoise Descotes, Norelyakin Kara, Myriam Decaussin-Petrucci, Eric Piaton, Florence Geiguer, Claire Rodriguez-Lafrasse, Jean E Terrier, Jonathan Lopez, Alain Ruffion
BACKGROUND: Urothelial bladder cancer (UBC) is characterised by a high risk of recurrence. Patient monitoring is currently based on iterative cystoscopy and on urine cytology with low sensitivity in non-muscle-invasive bladder cancer (NMIBC). Telomerase reverse transcriptase (TERT) is frequently reactivated in UBC by promoter mutations. METHODS: We studied whether detection of TERT mutation in urine could be a predictor of UBC recurrence and compared this to cytology/cystoscopy for patient follow-up...
August 8, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#14
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
August 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28628011/-criteria-for-selection-of-tumor-cells-and-prospects-for-specific-immunotherapy-for-bladder-cancer
#15
T Slavyanskaya, S -Salnikova, R Sepiashvili
Specific antitumor immunotherapy with autologous dendritic cell vaccines is one of the new approaches of modern medicine. For activation of dendritic cells highly immunogenic antigens are used, however optimal antigens in case of bladder cancer (BC) are still not researched. Cancer-testis antigens (CTA) are the most promising target in the context of creation of antitumor vaccines, because they are distinguished by pronounced immunogenicity, they are detected in different types of tumors and have limited pattern of expression in healthy tissues of grown-up organism...
May 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28627636/formulation-and-characterization-of-egcg-for-the-treatment-of-superficial-bladder-cancer
#16
Katarzyna Dettlaff, Maciej Stawny, Magdalena Ogrodowczyk, Anna Jelińska, Waldemar Bednarski, Dorota Wątróbska-Świetlikowska, Rick W Keck, Omar A Khan, Ibrahim H Mostafa, Jerzy Jankun
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease form limited to the urothelium. The rate of progression and recurrence is up to 40 and 70%, respectively. Urothelial cell carcinoma of the bladder is typically treated with transurethral resection. The cancerous cells can float onto the adjacent epithelium, increasing the risk of recurrence...
June 14, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28623648/systemic-chemotherapy-in-muscle-invasive-and-metastatic-bladder-cancer-present-and-future
#17
Gabriella Del Bene, Cora N Sternberg
Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future...
June 14, 2017: Urologia
https://www.readbyqxmd.com/read/28618711/re-eortc-nomograms-and-risk-groups-for-predicting-recurrence-progression-and-disease-specific-and-overall-survival-in-non-muscle-invasive-stage-ta-t1-urothelial-bladder-cancer-patients-treated-with-1-3-years-of-maintenance-bacillus-calmette-gu%C3%A3-rin
#18
https://www.readbyqxmd.com/read/28600686/a-critical-prognostic-analysis-of-neutrophil-lymphocyte-ratio-for-patients-undergoing-nephroureterectomy-due-to-upper-urinary-tract-urothelial-carcinoma
#19
Mesut Altan, Hakan Bahadır Haberal, Bülent Akdoğan, Haluk Özen
BACKGROUND: To determine preoperative serum complete blood count parameters that affects survival of patients who underwent surgery for upper urinary tract urothelial cancer (UUT-UC). METHODS: Since 1990, 150 patients underwent nephroureterectomy with bladder cuff excision for UUT-UC at Hacettepe University. Patients with a history of muscle-invasive bladder cancer, adjuvant chemotherapy or metastasis at the time of diagnosis were excluded. One hundred and thirteen patients without infective symptoms and with a full set of serum data were evaluated retrospectively...
June 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28586118/a-dna-hypermethylation-profile-reveals-new-potential-biomarkers-for-the-evaluation-of-prognosis-in-urothelial-bladder-cancer
#20
Jose I López, Javier C Angulo, Ana Martín, Manuel Sánchez-Chapado, Ana González-Corpas, Begoña Colás, Santiago Ropero
DNA hypermethylation has emerged as a molecular biomarker for the evaluation of cancer diagnosis and prognosis. We define a methylation signature of bladder cancer and evaluate whether this profile assesses prognosis of patients. Genome-wide methylation analysis was performed on 70 tumor and 10 normal bladder samples. Hypermethylation status of 1505 CpGs present in the promoter region of 807 genes was studied. Thirty-three genes were significantly hypermethylated in ≥10% of the tumors. Three clusters of patients were characterized by their DNA methylation profile, one at higher risk of dead of disease (p = 0...
September 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
keyword
keyword
105932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"